LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI

• Published in: BMJ global health 2017-02, Vol.2 (Suppl 2), p.A24-A24
• Main Authors: Tekete, Mamadou, Burhenne, Juergen, Fofana, Bakary, Toure, Sekou, Dama, Souleymane, Dara, Nianwalou, Traore, Oumar, Sidibe, Bouran, Djimde, Abdoulaye, Haefeli, Walter, Borrmann, Steffen
• Format: Article
• Language: English
• Subjects: Age; Global health; Malaria
• ISSN: 2059-7908; 2059-7908
• DOI: 10.1136/bmjgh-2016-000260.61

BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine's day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL.MethodsDuring a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed.ResultsWe included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis.The median concentration was 66% higher (p